Kevin Barlow Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 317 E Douglas St, Oneill, NE 68763 Phone: 402-336-2660 Fax: 402-336-2661 |
Angela Stepherson Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 317 E Douglas St, Oneill, NE 68763 Phone: 402-336-2660 |
Ms. Sheila Kay Johnston, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 404 E Highway 20, Oneill, NE 68763 Phone: 402-336-2000 Fax: 402-336-3727 |
Colton Joe Wilson Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 317 E Douglas St, Oneill, NE 68763 Phone: 402-336-2660 |
Mrs. Angela Marie Gray, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 316 E Highway 20, Oneill, NE 68763 Phone: 402-336-2000 |
News Archive
A team of scientists from the National Institutes of Health has discovered biological mechanisms that appear to prevent damage to the heart muscle's "power grid," the network of mitochondrial circuits that provide energy to cells.
Alma Lasers Ltd., a global leader in laser, light, radiofrequency and ultrasound-based aesthetic treatment devices, today announced the launch of its new iPixel series of innovative pixel modules for aesthetic fractional laser resurfacing.
Researchers in Sweden identified 386 pregnant women with pelvic girdle pain. Women were randomly divided into three groups; one received standard treatment (a pelvic belt and a home exercise programme), another received standard treatment plus acupuncture, and the third received standard treatment plus stabilising exercises to improve mobility and strength.
Chronic obstructive pulmonary disease, or COPD, is associated with increased risk of dying from a cardiovascular disease such as heart failure or a heart attack, as well as diseases not associated with the heart. However, COPD is not by itself associated with increased likelihood of having a stroke or a systemic embolism, according to a new research study.
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.
› Verified 2 days ago